49 results
PRE 14A
ELTX
Elicio Therapeutics, Inc.
17 Sep 24
Preliminary proxy
4:05pm
of the scope of the engagement of the independent auditor or on an individual, explicit, case-by-case basis before the independent auditor is engaged
8-K
EX-99.1
ELTX
Elicio Therapeutics, Inc.
13 Aug 24
Results of Operations and Financial Condition
4:33pm
-specific engagement driving therapeutic immune responses of increased magnitude, function and durability. We believe our AMP lymph node-targeted approach … . In preclinical models, we have observed lymph node-specific engagement driving immune responses of increased magnitude, function and durability
424B5
ELTX
Elicio Therapeutics, Inc.
28 Jun 24
Prospectus supplement for primary offering
9:08pm
a tail fee if any investor who was contacted or introduced to us by Jones during the term of its engagement, provides us with capital in any public … or private offering of equity, equity linked, or preferred securities during the six-month period following the termination or expiration of our engagement
8-K
EX-1.1
ELTX
Elicio Therapeutics, Inc.
28 Jun 24
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
7:08pm
an alleged breach of fiduciary duty in connection with the offering of the Securities.
(c) Notwithstanding this Section 11, the Engagement Letter dated
424B5
ELTX
Elicio Therapeutics, Inc.
27 Jun 24
Prospectus supplement for primary offering
4:42pm
was contacted or introduced to us by Jones during the term of its engagement, provides us with capital in any public or private offering of equity, equity … linked, or preferred securities during the six-month period following the termination or expiration of our engagement agreement with Jones, except
8-K
EX-99.1
jso6dgy3
29 Mar 24
Results of Operations and Financial Condition
8:35am
8-K
EX-99.2
ksxw7vx r4sthgq
9 Jan 24
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
8:11am
8-K
EX-99.1
rlkago936mq
9 Nov 23
Results of Operations and Financial Condition
4:41pm
8-K
EX-99.1
384nf5j qmstenkozxhu
3 Nov 23
Other Events
5:10pm
8-K
EX-99.2
5o69w5m9nc058
27 Sep 23
Other Events
5:41pm
8-K
EX-99.1
6ucy3jsxa6y
27 Sep 23
Other Events
5:41pm
8-K
EX-99.1
i2jyga287pzqgo muosq
7 Sep 23
Other Events
8:00am
8-K
EX-99.1
dhwck9854ij1e64q
11 Aug 23
Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides
11:42am
8-K
EX-99.1
fi6sxbal
5 Jun 23
Other Events
8:00am
8-K
EX-99.3
zck3jlm9
2 Jun 23
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
4:36pm
8-K
EX-99.5
wi0h dt61
2 Jun 23
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
4:36pm
8-K
EX-99.2
a93drgr
2 Jun 23
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
4:36pm
8-K
s5cdp 96w
2 Jun 23
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
4:36pm
8-K
EX-10.8
glcadc f8l0deyd5
2 Jun 23
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
4:36pm